Phase 2 Neck Clinical Trials
245 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 245 trials
Recruiting
Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Head and Neck Squamous Cell CarcinomaStage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8+13 more
ECOG-ACRIN Cancer Research Group189 enrolled676 locationsNCT02734537
Recruiting
Phase 2
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
Head and Neck Cancer Squamous Cell Carcinoma
VSPharmTech Co.,Ltd.30 enrolled3 locationsNCT06959082
Recruiting
Phase 2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell Carcinoma+15 more
National Cancer Institute (NCI)180 enrolled70 locationsNCT07195734
Recruiting
Phase 1Phase 2
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Triple-Negative Breast CancerMelanomaNon-small Cell Lung Cancer+6 more
AstraZeneca60 enrolled13 locationsNCT07115043
Recruiting
Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell Carcinoma+2 more
National Cancer Institute (NCI)188 enrolled178 locationsNCT04671667
Recruiting
Phase 2
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Head and Neck CancerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma+3 more
Glenn J. Hanna25 enrolled2 locationsNCT06239220
Recruiting
Phase 2
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Squamous Cell Carcinoma of the Head and NeckDrug TherapyOropharynx+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06223568
Recruiting
Phase 2
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Squamous Cell Carcinoma of Head and Neck
Barbara Burtness50 enrolled1 locationNCT05317000
Recruiting
Phase 2
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Head and Neck CancerHearing Loss
National Institute on Deafness and Other Communication Disorders (NIDCD)224 enrolled5 locationsNCT04915183
Recruiting
Phase 1Phase 2
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
Head and Neck CancerThoracic CancerTesticular Cancer+1 more
University of Arizona25 enrolled1 locationNCT07407582
Recruiting
Phase 2
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled222 locationsNCT05136196
Recruiting
Phase 1Phase 2
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC287 enrolled56 locationsNCT06385080
Recruiting
Phase 2
Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University102 enrolled1 locationNCT07632339
Recruiting
Phase 1Phase 2
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Colorectal, CancerEsophageal CancerGastric Cancer+5 more
Perspective Therapeutics112 enrolled8 locationsNCT06710756
Recruiting
Phase 2
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Head and Neck CarcinomaHead and Neck CancerOral Cancer+1 more
Case Comprehensive Cancer Center30 enrolled1 locationNCT06627270
Recruiting
Phase 2
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello65 enrolled17 locationsNCT06856213
Recruiting
Phase 1Phase 2
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb1,109 enrolled47 locationsNCT04895709
Recruiting
Phase 2
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage III Laryngeal Cancer AJCC v8+19 more
National Cancer Institute (NCI)44 enrolled6 locationsNCT06980038
Recruiting
Phase 2Phase 3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics650 enrolled173 locationsNCT06788990